Bimatoprost
- Generic Name
- Bimatoprost
- Brand Names
- Durysta, Latisse, Lumigan, Ganfort
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 155206-00-1
- Unique Ingredient Identifier
- QXS94885MZ
Overview
Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
Background
Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
Indication
Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments. Bimatoprost is also indicated to treat eyelash hypotrichosis.
Associated Conditions
- Hypotrichosis of the eyelashes
- Increased Intra Ocular Pressure (IOP)
Clinical Trials
Login Required
To view more clinical trials, please log in to your account.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2011/12/12 | N/A | Completed | |||
2011/11/03 | Phase 4 | Completed | |||
2011/10/07 | Phase 4 | Completed | |||
2011/08/31 | Phase 3 | Terminated | |||
2011/07/12 | Phase 3 | Completed | |||
2011/07/12 | Phase 3 | Completed | |||
2011/07/06 | Phase 4 | Completed | Kenneth Beer | ||
2011/03/29 | Phase 2 | Completed | |||
2011/03/29 | Phase 2 | Completed | |||
2011/02/18 | Phase 4 | Completed |
FDA Approved Products
Login Required
To view more FDA approved products, please log in to your account.
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
|---|
No FDA products found
No FDA products found for this drug
EMA Approved Products
Login Required
To view more EMA approved products, please log in to your account.
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
|---|
No EMA products found
No EMA products found for this drug
Singapore Approved Products
Login Required
To view more Singapore approved products, please log in to your account.
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. | Online |
|---|
No Singapore products found
No Singapore products found for this drug
China Approved Products
Login Required
To view more China approved products, please log in to your account.
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
|---|
No China products found
No China products found for this drug
Australia Approved Products
Login Required
To view more Australia approved products, please log in to your account.
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
|---|
No Australia products found
No Australia products found for this drug